Regulating the economic evaluation of pharmaceuticals and medical devices: a European perspective (Q35051437)

6 August 2017

title

Regulating the economic evaluation of pharmaceuticals and medical devices: a European perspective (English)

1 reference

6 August 2017

1 reference

Richard Cookson

1

1 reference

6 August 2017

John Hutton

series ordinal

2

1 reference

6 August 2017

publication date

1 February 2003

1 reference

6 August 2017

1 reference

6 August 2017

volume

63

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

167-178

1 reference

Pharmacoeconomics in European decision-making

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2802%2900063-5

7 January 2021

Current trends in the use of pharmacoeconomics and outcomes research in europe

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2802%2900063-5

7 January 2021

Why we need observational studies to evaluate the effectiveness of health care

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2802%2900063-5

7 January 2021

Some guidelines on the use of cost effectiveness league tables

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2802%2900063-5

7 January 2021

Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2802%2900063-5

7 January 2021

Explanatory and pragmatic attitudes in therapeutical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2802%2900063-5

7 January 2021

Modelling in economic evaluation: an unavoidable fact of life

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2802%2900063-5

7 January 2021

Regulating the pharmaceutical industry

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2802%2900063-5

7 January 2021

Being a modern pharmaceutical company: involves making information available on clinical trial programmes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2802%2900063-5

7 January 2021

An amnesty for unpublished trials. One year on, many trials are unregistered and the amnesty remains open

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2802%2900063-5

7 January 2021

Pharmacoeconomic analyses: making them transparent, making them credible

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2802%2900063-5

7 January 2021

Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2802%2900063-5

7 January 2021

Cost-effectiveness league tables: More harm than good?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2802%2900063-5

7 January 2021

Not playing with a full DEC: why development and evaluation committee methods for appraising new drugs may be inadequate

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2802%2900063-5

7 January 2021

Intergenerational equity: an exploration of the 'fair innings' argument

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2802%2900063-5

7 January 2021

Money or your life? The health-wealth trade-off in pharmaceutical regulation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2802%2900063-5

7 January 2021

The pharmaceutical industry--to whom is it accountable?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8510%2802%2900063-5

7 January 2021

10.1016/S0168-8510(02)00063-5

Identifiers

DOI

1 reference

6 August 2017

1 reference